EUCTR2006-003886-15-IT进行中（未招募）不适用
Steady state telithromycin pharmacokinetics and pharmacodynamic in adult patients with mild-moderate acute exacerbation of chronic obstructive pulmonary disease treated with a standard oral dose 800 mg od for 5 days - TELI AECOPD
SANOFI-AVENTIS S.P.A0 个研究点目标入组 25 人开始时间: 2007年1月10日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Adult inpatients, either sex, aged 18 years or older; documented history of mild-moderate chronic bronchitis/chronic obstructive pulmonary disease COPD as defined by ERS/ATS criteria and with a basal FEV1 / 50 and with FEV1 / FVC / 70 and who have had at least one or more episode of acute exacerbation in the previous year; clinical diagnosis of AECOPD based on the following clinical signs and symptoms at least two of any of the following Winnipeg II increased in sputum purulence change in color and/or increased in sputum volume and/or increased dyspnea with or without other symptoms like fever, cough, ect.; sufficient volumes of spontaneous sputum to permit collection of specimens for gram stain and bacteriological culture; negative chest radiography posterior/anterior and lateral views to rule out a diagnosis of pneumonia within 48 hours before initiation of study medication or at the latest 24 hours after initiation of study medication.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Main criteria in relation with study protocol current asthma, with a known diagnosis of bronchiectasis, cystic fibrosis, lung cancer or lung metastases, or active pulmonary tuberculosis; acute respiratory failure or patients requiring aggressive airway management; requiring parenteral antibiotic therapy; treated with antibiotics within 30 days prior to enrollment; with a maintenance oral corticosteroid therapy; with known impaired renal function serum creatinine 1.5 mg/dL ; immunocompromission. Main criteria in relation with study treatment with known impaired hepatic function sGOT, sGPT or serum bilirubin more than 2-fold the normal values ; with suspected or known hypersensitivity to, or suspected serious adverse reaction to the study medication, or macrolide class of antibiotics; with a known history of long QTc syndrome e.g., personal or family history of syncope or arrhythmia ; treated within 2 weeks prior inclusion, or requiring treatment during study medication, with CYP3A4 inducers such as rifampicine, phenyto n, carbamazepine, phenobarbital, and St John s Wort; who will require on-study treatment with medications known to have contraindicated drug interactions with the study medication and/or macrolides, in general, including but not limited to ergot alkaloid derivatives, terfenadine, cisapride, astemizole, pimozide, bromocriptine, cabergoline, pergolide and statins for those patients who are not allowed to stop their statin treatment simvastatin, lovastatin, atorvastatin .
研究者
相似试验
已完成
不适用
The pharmacokinetic effect of clarithromycin on the AUC0-12h of linezolid in multidrug-resistant and extensively drug-resistant tuberculosis patientstuberculosis10028440TBNL-OMON35904niversitair Medisch Centrum Groningen7
进行中（未招募）
不适用
The effect of combining two anti-tuberculosis drugs, clarithromycin and linezolid, on the amount of clarithromycin and linezolid in the blood of severe tuberculosis patients.Multidrug-resistant and extensively drug-resistant tubeculosis (MDR/XDR-TB)MedDRA version: 14.0Level: LLTClassification code 10043148Term: TBSystem Organ Class: 10021881 - Infections and infestationsEUCTR2011-000513-39-NLniversity Medical Center Groningen8
进行中（未招募）
不适用
Population pharmacokinetic/pharmacodynamic and tolerability clinical trial in patients suffering from acute post-operative pain - Dexibuprofen ready oral suspensiopharmakodynamik: Acute post-operative pain after an operation (surgery) (acute is defined as within 4 hours after end of surgery).pharmakokinetik: Acute post-operative pain is not necessary. Trial medication will be used after surgery as defined in Amendment III (Trial Protocol).MedDRA version: 8.1Level: LLTClassification code 10054711EUCTR2005-006069-15-ATGebro Pharma GmbH192
进行中（未招募）
1 期
Measuring the concentration profile of the antibiotic temocillin in the blood of childreMale or female patient requiring temocillin a. for the treatment of urinary tract infections, orb. for the treatment of suspicion of cholangitis associated with cirrhosis, orc. as antibiotic prophylaxis following an hepatic transplant.MedDRA version: 18.1Level: PTClassification code 10024714Term: Liver transplantSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 18.1Level: HLTClassification code 10004607Term: Bile duct infections and inflammationsSystem Organ Class: 10019805 - Hepatobiliary disordersMedDRA version: 18.1Level: SOCClassification code 10042613Term: Surgical and medical proceduresSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 18.1Level: PTClassification code 10046571Term: Urinary tract infectionSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 18.1Level: HLGTClassification code 10021879Term: Infections - pathogen unspecifiedSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 18.1Level: SOCClassification code 10021881Term: Infections and infestationsSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 18.1Level: HLTClassification code 10019704Term: Hepatic therapeutic proceduresSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 18.1Level: PTClassification code 10008605Term: Cholangitis acuteSystem Organ Class: 10019805 - Hepatobiliary disordersMedDRA version: 18.1Level: SOCClassification code 10019805Term: Hepatobiliary disordersSystem Organ Class: 10019805 - Hepatobiliary disordersMedDRA version: 18.1Level: HLGTClassification code 10019818Term: Hepatobiliary therapeutic proceduresSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 18.1Level: HLGTClassification code 10004606Term: Bile duct disordersSystem Organ Class: 10019805 - Hepatobiliary disordersMedDRA versEUCTR2014-004224-22-BEniversité catholique de Louvain45
进行中（未招募）
不适用
Pharmacokinetics and Tolerability of AV104 (Nalmefene hydrochloride) buccal films in Cholestatic Liver Disease Subjects.CTRI/2022/05/042461Avior Bio Inc